Skip to Content

Posts tagged with "The Central Nervous System"

  • Alzheimer's Disease

    The Case of Verge Genomics

    A number of people have passed along the recent press stories about Verge Genomics, a new company out of YCombinator that has just raised $32 million for neuroscience drug discovery. Now that, as literally anyone who’s ever done it can tell you, is a hard field of a hard field, and I wish Verge good… Read More
  • Analytical Chemistry

    The Phosphoproteomic Landscape Speaks – What Did It Say, Again?

    Medicinal chemists are extremely familiar with G-protein coupled receptors (GPCRs), and it’s a safe bet that any pretty much any neurotransmitter (for example) that can be named by the general public is a GPCR ligand, too. Serotonin, dopamine, histamine – all the classics are there, and that’s reflected in the number of marketed d… Read More
  • The Central Nervous System

    A Molecular Mechanism for Alcoholism?

    If this works out, it’s something that people have been trying to find for a long time: what exactly are the genetic/biochemical vulnerabilities that make a person susceptible to alcoholism? It’s long been suspected that there must be some, but untangling these things from sheer behavioral/environmental effects is extremely difficult. I… Read More
  • Alzheimer's Disease

    Alzheimer’s and Infectious Disease: For Real

    I’ve written a couple of times over the years about the idea that Alzheimer’s disease might have an infectious component to it. That’s been proposed many times, but it’s fair to say that it’s never caught on. For one thing, the amyloid hypothesis has always had a lot more going for it. I realize that… Read More
  • Business and Markets

    Welcome to Right to Try

    Update: Brainstorm has now abandoned their Right-to-Try approach. Who’s next? That didn’t take long. That didn’t take long at all. The federal “Right to Try” bill was just signed the other week, and we already have a company that’s willing – no, eager – to try it out. I will now cruelly caricature som… Read More
  • Drug Assays

    Tecfidera Explained

    One of the more unusual drugs on the market is Tecfidera (dimethyl fumarate). I went into its history a bit in this post, if you’re wondering how a molecule that small and unfunctionalized became a multiple sclerosis drug. As that shows, it went into trials for the disease with quite a bit of clinical rationale… Read More
  • The Central Nervous System

    Understanding Antidepressants – Or Not

    I was talking with a colleague the other day who’s done a lot of work on central nervous system disease over the years, and it reminded me of something that I said years ago on this blog (and was the first time I was quoted in the Wall Street Journal). Was that an opinion about… Read More
  • Regulatory Affairs

    Kratom and the FDA

    The FDA has made an announcement about kratom, a plant preparation (Mitragyna speciosa) that (depending on who you ask) is a drug of abuse or a way for people to get off of other drugs of abuse. Specifically, it’s used as a way to mitigate opioid withdrawal symptoms, which is reason enough to wonder if it… Read More
  • Biological News

    CRISPR and Axovant: What the Market Thinks

    Let’s go to the NASDAQ for some insight on a couple of recent biopharma stories. First off is Axovant, a company that’s interesting in a number of distressing ways. I last wrote about them here, after their Alzheimer’s candidate came up short in the clinic, which was a development that surprised no one who had… Read More
  • Clinical Trials

    Expensive Shams Are the Way to Go, Apparently

    Prepare to be weirded out a bit. We’re going to talk about the placebo effect again – actually, we’re going to talk about its evil twin, the nocebo effect. In the same way that a placebo is an inactive/nonexistent agent that people think is doing them good, a nocebo is one that people believe is… Read More
123...